You just read:

Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis

News provided by

Novartis Pharmaceuticals Corporation

Jul 14, 2017, 15:51 ET